Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 236 participants.

Also called NCT03597412

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 236 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03597412
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03597412. Randomized; no masking; primary purpose treatment. Start 2018-10-17 (actual); primary completion 2020-08-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
Acronym
MIRA
Condition
Atherosclerotic Cardiovascular Disease
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Rosuvamibe
Intervention (Drug)
Monorova
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct03597412
Content hash
024a9ba1e715b28c166276dddc04a6f929ef8fa900a46ba26cedd8958f3a9f5c